Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

See-Tarn Woon

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Neoplasia (New York, N.Y.)|September 9, 2010
Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of actionRomy Brauer, Liang-Chuan S Wang, See-Tarn Woon, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Journal of Paediatrics and Child Health|May 12, 2026
Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in OceaniaCecilia Verryt, Paul Gray, Peter McNaughton, et al.
American Journal of Human Genetics|August 18, 2015
Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable ImmunodeficiencyManfred Fliegauf, Vanessa L Bryant, Natalie Frede, et al.
The Journal of Experimental Medicine|April 20, 2022
A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotesPaul Bastard, Kuang-Chih Hsiao, Qian Zhang, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Neoplasia (New York, N.Y.)|September 9, 2010
Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of actionRomy Brauer, Liang-Chuan S Wang, See-Tarn Woon, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Journal of Paediatrics and Child Health|May 12, 2026
Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in OceaniaCecilia Verryt, Paul Gray, Peter McNaughton, et al.
American Journal of Human Genetics|August 18, 2015
Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable ImmunodeficiencyManfred Fliegauf, Vanessa L Bryant, Natalie Frede, et al.
The Journal of Experimental Medicine|April 20, 2022
A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotesPaul Bastard, Kuang-Chih Hsiao, Qian Zhang, et al.
Pageof 7